Bangladesh’s pharmaceutical industry faces the challenge of losing its Least Developed Country (LDC) status, expected in 2026. This transition may result in the loss of its ability to produce generic drugs without patent restrictions. While the European Union may grant a grace period, the industry must prepare for potential patent claims from global pharmaceutical firms.